AB0076 LONG-TERM SAFETY OF VACCINATION FOR COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES AND PSORIASIS: DATA FROM THE SAR-CoVAC REGISTRY
Authors: C. A. Isnardi, B. M. Virasoro, M. E. D´angelo, D. A. Pereira, I. E. Petkovic, Y. Tissera, M. D. L. A. Correa, C. Pisoni, G. F. Rodriguez Gil, R. Quintana, A. K. Cogo, J. Kreimer, C. G. Alonso, N. Kogan, A. L. Toledo, M. A. Alfaro, M. Cosatti, R. Nieto, L. Garcia, A. Rollano Perasso, Z. Troyano, E. Debernardi, G. Pons-Estel, E. E. Schneeberger
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Vaccination for COVID-19 has been widely used in our country in patients with rheumatic diseases (RD) and psoriasis (Ps); However, no randomized controlled clinical study has been performed in this population. <h3>Objectives:</h3> To describe the characteristics of vaccination for COVID-19 in patients with RD and Ps in Argentina and its long-term safety. <h3>Methods:</h3> SAR-CoVAC is a national, longitudinal and observational registry, in which patients ≥18 years of age, with a diagnosis of RD and/or Ps, who have received at least one dose of COVID-19 vaccine, were consecutively included. For this analysis, data collected from June 2021 to May 2023 were included. Sociodemographic, clinical, therapeutic data, vaccines applied, development of adverse events (AEs), disease flares and new immune-mediated manifestations, and SARS-CoV-2 infection after vaccination and its severity were recorded. <h3>Results:</h3> A total of 2264 patients were included, the majority female (78.4%) with a mean age of 56.5 years (SD 14.5). Nearly half (47.3%) had at least one comorbidity, hypertension and dyslipidemia being the most frequent. The most prevalent diseases were rheumatoid arthritis (39.0%) and osteoarthritis (16.7%). At the time of starting the vaccination regimen, 72.7% were in remission and low activity, 19.8% received glucocorticoids, 30.1% biological agents or small molecules. Regarding the primary vaccination regimen, the most frequently used vaccines were Gam-COVID-Vac, ChAdOx1 nCoV-19 and BBIBP-CorV, mostly in the form of homologous regimens (67.2%). Figure 1 shows the vaccines used according to dose. 39% of the patients reported at least one AE during any of the vaccines received, a total of 1211 AEs in 5887 doses. The most frequent were local hypersensitivity and flu-like syndrome. Mostly mild-moderate and only 8 events led to hospitalization and 2 cases of anaphylaxis were recorded. The total incidence of AEs was 20.6 events per 100 doses applied, being significantly lower for BBIBP-CorV (p&lt;0.05) (Table 1). 59 cases of disease flare were identified and 2 of vaccine-associated thrombocytopenia thrombosis events. No new immune mediated manifestation was reported. <h3>Conclusion:</h3> In this cohort in which the COVID-19 vaccines available in our country were evaluated, they proved to be safe in patients with RD and/or Ps. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Carolina Ayelen Isnardi Pfizer, Belén María Virasoro: None declared, Maria Eugenia D´Angelo: None declared, Dora Aida Pereira: None declared, Ingrid Eleonora Petkovic: None declared, Yohana Tissera: None declared, Maria de los Angeles Correa: None declared, Cecilia Pisoni: None declared, Gustavo Fabian Rodriguez Gil: None declared, Rosana Quintana: None declared, Adriana Karina Cogo: None declared, Jennifer Kreimer: None declared, Carla G Alonso: None declared, Nora Kogan: None declared, Ana Laura Toledo: None declared, Maria Agustina Alfaro: None declared, Micaela Cosatti: None declared, Romina Nieto: None declared, Lucila Garcia: None declared, Alejandra Rollano Perasso: None declared, Zaida Troyano: None declared, Emilia Debernardi: None declared, Guillermo Pons-Estel: None declared, Emilce Edith Schneeberger: None declared.